Shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) fell 9.1% on Friday . The company traded as low as $0.39 and last traded at $0.40. 1,059,999 shares were traded during mid-day trading, an increase of 76% from the average session volume of 600,900 shares. The stock had previously closed at $0.44.

A number of brokerages have weighed in on PLX. Zacks Investment Research cut Protalix Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 14th. HC Wainwright set a $4.00 price target on Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Tuesday, October 9th.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last announced its quarterly earnings results on Wednesday, November 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06). The business had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $8.00 million. During the same quarter last year, the business earned ($0.09) EPS.

A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Renaissance Technologies LLC increased its position in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 13.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,614,700 shares of the company’s stock after acquiring an additional 305,200 shares during the quarter. Renaissance Technologies LLC owned about 1.80% of Protalix Biotherapeutics worth $1,124,000 at the end of the most recent quarter.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at

About Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Further Reading: Do Tariffs Work?

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.